Stockscreener 앱 받기
0.0021
0.00%
0.00
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
NKGen Biotech to Present on Troculeucel for - GlobeNewswire
NKGen Biotech to Present on Potential of Troculeucel in - GlobeNewswire
NKGen Biotech Expands Financing Through Convertible Note Issuance - TipRanks
NKGen Biotech Korea Co., Ltd. Revenue Breakdown – KRX:182400 - TradingView
NKGen Biotech Inc. Revenue Breakdown – OTC:NKGNW - TradingView
NKGen Biotech Inc. Revenue Breakdown – OTC:NKGN - TradingView
Price to earnings forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Price to sales forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
Price to book forward of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Amends Term Loan and Collateral Agreement - TipRanks
NKGen Biotech (NKGN) alters collateral on $5M credit facility - Stock Titan
Enterprise value to revenue forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to book forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to earnings forward of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Number of employees of NKGen Biotech Inc. – OTC:NKGNW - TradingView
Price to sales forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
NKGen Biotech takes Alzheimer’s research global - Longevity.Technology
Price to earnings forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
Enterprise value to revenue forward of NKGen Biotech Korea Co., Ltd. – KRX:182400 - TradingView
NKGen Biotech announces new funding to regain compliance with reporting obligations and listing standards - MSN
NKGen Biotech to present Alzheimer’s drug trocu... - Pluang
NKGen's CEO to Present Alzheimer’s Cell Therapy at Seoul Forum - Stock Titan
NKGen Biotech to Present at the 2026 BIOCHINA Global Forum - GlobeNewswire
Alzheimer’s Disease Pipeline Accelerates as 200+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
NKGen Biotech Expands Convertible Financing Through New Agreement - The Globe and Mail
NKGen Biotech (NKGN) takes $2.42M note, lifts consideration shares - Stock Titan
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - Benzinga
A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company - PR Newswire
NKGen Biotech Expands Financing Through New Convertible Loan - TipRanks
NKGen Biotech (NKGN) expands AlpineBrook convertible deal with $412.5K note and new warrant - Stock Titan
Nkgen Biotech expands clinical trial site network for Alzheimer’s disease program across US - marketscreener.com
Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US - TradingView
NKGen Biotech Inc. is expanding its Alzheimer’s disease clinical trial site network nationwide across the United States. - Bitget
NKGen Biotech Expands Clinical Trial Site Network for Alzheimer’s Disease Program Across U.S. to Improve Patient Access and Support Enrollment - marketscreener.com
New Alzheimer’s trial sites move NK cell therapy closer to East Coast patients - Stock Titan
NKGen Biotech Expands Clinical Trial Site Network for - GlobeNewswire
Number of shareholders of NKGen Biotech Inc. – OTC:NKGN - TradingView
NKGen Biotech Secures Additional Convertible Financing and Warrants - TipRanks
NKGen Biotech (NKGN) expands dilutive note deal with 12M+ shares, warrant - Stock Titan
NKGN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
NKGen Biotech Announces Major Convertible Financing and Governance Shift - TipRanks
NKGen Biotech (NKGN) inks $39,922,134.22 secured convertible loan and control rights - Stock Titan
NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer’s and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit - marketscreener.com
NKGen Biotech to Present Troculeucel Mechanism Data in - GlobeNewswire
Former Bio Firm Executive Charged for Insider Trading on Drug Approval Tip - Seoul Economic Daily
NKGen Biotech Reports Combined Phase 1 Troculeucel Data - GlobeNewswire
Troculeucel Linked to Plasma GFAP Changes and Cognitive Measures in Early Alzheimer Disease Studies - NeurologyLive
Troculeucel may boost cognition, new Alzheimer’s data shows - Longevity.Technology
NKGen Biotech to Present Integrated Phase 1 Clinical and - GlobeNewswire
Nkgen Biotech amends loan agreement to secure additional $343,000 funding - Investing.com
NKGen Biotech increases loan principal by $251,000 under amended agreement - Investing.com
NKGen Biotech amends loan agreement and extends forward purchase deal - Investing.com
NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. to Scientific Advisory Board - Barchart.com
NKGen Biotech enters $25.8 million secured note agreement with AlpineBrook Capital - Investing.com
NKGen Biotech, Inc. Issues Statement on Recent Board - GlobeNewswire
NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - The Manila Times
NKGen Biotech enters $2.5 million stock and warrant agreement with Asia Advisors - Investing.com
NKGen Biotech to Present on the Use of Troculeucel for - GlobeNewswire
HWH Stock Price and Chart — NASDAQ:HWH - TradingView
NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. - GlobeNewswire
NKGen Biotech Presents Troculeucel Mechanism of Action with - GlobeNewswire
FDA clears troculeucel for expanded access program - ALS News Today
NKGen Biotech to Present at the Alzheimer’s Association International Conference 2025 - GlobeNewswire
NKGen Biotech Gets FDA Expanded Access - Orange County Business Journal
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - The Manila Times
NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient Who Continued to Decline Cognitively While on Prior Amyloid-Targeting Therapy - The Manila Times
NKGen administers first dose of NK cell therapy to Alzheimer's patient - Investing.com Canada
0.05%
0.82%
자본화:
|
볼륨(24시간):